Surrozen (NASDAQ:SRZN) Stock Rating Upgraded by Wall Street Zen

Surrozen (NASDAQ:SRZN) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other analysts also recently issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price target (up from $32.00) on shares of Surrozen in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $38.00.

Surrozen Stock Performance

Surrozen stock opened at $28.90 on Friday. Surrozen has a 1 year low of $5.90 and a 1 year high of $29.59. The firm has a 50 day moving average price of $24.67 and a 200 day moving average price of $19.00. The company has a market cap of $247.70 million, a price-to-earnings ratio of -0.87 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). The company had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%. Sell-side analysts predict that Surrozen will post -8.49 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the stock in a transaction on Tuesday, March 24th. The stock was bought at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the transaction, the insider directly owned 736,554 shares of the company’s stock, valued at $18,185,518.26. The trade was a 16.93% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Tim Kutzkey acquired 18,052 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were purchased at an average price of $19.60 per share, for a total transaction of $353,819.20. Following the purchase, the director directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 330,291 shares of company stock worth $7,478,785 in the last 90 days. 45.18% of the stock is owned by company insiders.

Institutional Investors Weigh In On Surrozen

A number of large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares during the period. Stonepine Capital Management LLC boosted its position in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Stempoint Capital LP grew its stake in shares of Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after acquiring an additional 445,713 shares in the last quarter. Armistice Capital LLC acquired a new stake in shares of Surrozen during the second quarter valued at about $536,000. Finally, Braidwell LP purchased a new stake in shares of Surrozen during the second quarter worth about $1,252,000. 66.57% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buying: TCG Crossover GP II purchased 106,658 shares on March 24 (~$2.63M at ~$24.69) as part of a recent string of purchases, materially increasing its stake and signaling insider conviction that can support the stock. InsiderTrades: Major Shareholder Purchases
• Positive Sentiment: Follow-on insider buy: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90 (SEC filing disclosed), reinforcing the same insider-buy signal. American Banking News: Tcg Crossover Acquires Shares
• Positive Sentiment: Analyst support: Cantor Fitzgerald gave an “Overweight” rating and a $40 target, and HC Wainwright reiterated a “Buy” and raised targets/longer-term EPS forecasts — both items tend to attract buyer interest and can lift sentiment. American Banking News: Cantor Fitzgerald Rating American Banking News: HC Wainwright Buy Rating
• Positive Sentiment: HC Wainwright commentary on FY2030 shows a materially less-negative multi-year EPS path in their model (raises to FY2026–FY2029/FY2030 estimates), suggesting improving operating/profitability assumptions versus consensus. American Banking News: HC Wainwright FY2030 Comments
• Neutral Sentiment: Short-interest / days-to-cover data in some reports appears inconsistent (some sources show zero shorts / NaN), so treat short-interest as unreliable in explaining the move today.
• Negative Sentiment: Lifesci Capital cut near-term EPS estimates across Q1–Q4 2026 and trimmed FY2026, signaling more conservative short-term cash/burn or program timing assumptions — a reminder of execution and cash-risk that could cap upside. MarketBeat: Analyst Estimate Changes

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.